Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270470 | 1.00 | ALOX5 (0.51) | ALOX5CYP1A2SMN1; SMN2PYCR1LMNA | |
| SCHEMBL2576026 | 1.00 | ALOX5 (0.51) | ALOX5CYP1A2SMN1; SMN2PYCR1LMNA | |
| SCHEMBL1448846 | 0.84 | ESR1 (0.42) | ALOX5CYP1A2LMNAALDH1A1CYP2C19 | |
| SCHEMBL2429212 | 0.84 | ESR1 (0.42) | ALOX5CYP1A2LMNAALDH1A1CYP2C19 | |
| SCHEMBL20492498 | 0.82 | ALOX5 (0.41) | ALOX5CYP1A2SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2198695 | 0.81 | MAPT (0.39) | ALOX5SMN1; SMN2PYCR1LMNAKMT2A | |
| SCHEMBL8155052 | 0.81 | SMN1; SMN2 (0.40) | ALOX5CYP1A2SMN1; SMN2LMNAMEN1 | |
| SCHEMBL15609345 | 0.81 | ALDH1A1 (0.43) | ALOX5SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL6825359 | 0.80 | SMN1; SMN2 (0.39) | ALOX5CYP1A2SMN1; SMN2LMNAMEN1 | |
| SCHEMBL16243710 | 0.80 | LMNA (0.42) | ALOX5CYP1A2SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865885-A | Near infrared fluorescent compound for early diagnosis and treatment of glioma, and preparation method and application thereof | 南京师范大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | ALOX5 4734/4885CYP1A2 4055/4885SMN1; SMN2 3452/4885 |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | ALOX5 4003/4885CYP1A2 4534/4885SMN1; SMN2 4230/4885 |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | PTGER1, PTGER2, PTGER3 | ALOX5 45/4885CYP1A2 48/4885SMN1; SMN2 1385/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | ALOX5 1564/4885CYP1A2 17/4885SMN1; SMN2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.